Counteracting quasispecies adaptability: Extinction of a ribavirin-resistant virus mutant by an alternative mutagenic treatment

PLoS ONE

Volumn 4, Issue 5, 2009, Pages

  Perales, Celia ^a,b   Agudo, Rubén ^a,b   Domingo, Esteban ^a,b  

^a CSIC   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GUANIDINE; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; ANTIVIRUS AGENT; DRUG DERIVATIVE; MUTAGENIC AGENT; VIRUS PROTEIN; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONTROLLED STUDY; FOOT AND MOUTH DISEASE VIRUS; MUTAGENESIS; MUTAGENIC ACTIVITY; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; WILD TYPE; ANTIVIRAL RESISTANCE; CELL CULTURE; DRUG EFFECT; GENETICS; METABOLISM; MUTATION; SPECIES DIFFERENCE;

FOOT-AND-MOUTH DISEASE VIRUS;

AMINO ACID SUBSTITUTION; ANTIVIRAL AGENTS; CELLS, CULTURED; DRUG RESISTANCE, VIRAL; FOOT-AND-MOUTH DISEASE VIRUS; MUTAGENESIS; MUTAGENS; MUTATION; RIBAVIRIN; RNA REPLICASE; RNA, VIRAL; SPECIES SPECIFICITY; VIRAL PROTEINS;

EID: 65849141020     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005554     Document Type: Article

References (93)

1. Domingo E, ed (2006) Quasispecies: Concepts and Implications for Virology. Current Topics in Microbiology and Immunology.
2. Domingo E, Escarmís C, Menéndez-Arias L, Perales C, Herrera M, et al. (2008) Viral quasispecies: dynamics, interactions and pathogenesis. In: Origin and Evolution of Viruses, Domingo E, Parrish C, Holland JJ, eds. Oxford: Elsevier. pp 87-118.
3. Drake JW, Holland JJ (1999) Mutation rates among RNA viruses. Proc Natl Acad Sci USA 96: 13910-13913.
4. Figlerowicz M, Alejska M, Kurzynska-Kokorniak A, Figlerowicz M (2003) Genetic variability: the key problem in the prevention and therapy of RNA-based virus infections. Medicinal Res Reviews 23: 488-518.
5. Holland JJ, Spindler K, Horodyski F, Grabau E, Nichol S, et al. (1982) Rapid evolution of RNA genomes. Science 215: 1577-1585.
6. Quer J, Martell M, Rodriguez F, Bosch A, Jardi R, et al. (2008) The impact of rapid evolution of hepatitis viruses. In: Domingo E, Parrish CR, Holland JJ, eds. Origin and Evolution of Viruses, 2nd edition. Amsterdam: Elsevier, Academic Press. pp 303-349.
7. Villarreal LP (2008) The Widespread Evolutionary Significance of Viruses. In: Domingo E, Parrish CR, Holland JJ, eds. Origin and Evolution of Viruses, 2nd edition. pp 393-416 477-516.
8. Müller V, and, Bonhoeffer S (2008) Intra-host Dynamics and Evolution of HIV Infections. In: Domingo E, Parrish CR, Holland JJ, eds. Origin and evolution of viruses 2a Edition. 279 p.
9. Hanley KH, Weaver SC (2008) Arbovirus Evolution. In: Domingo E, Parrish CR, Holland JJ, eds. Origin and evolution of viruses 2a Edition. Oxford: Elsevier. 351 p.
10. Meng XJ (2000) Heterogeneity of porcine reproductive and respiratory syndrome virus: implications for current vaccine efficacy and future vaccine development. Vet Microbiol 74: 309-329.
11. Holland JJ, Domingo E, de la Torre JC, Steinhauer DA (1990) Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol 64: 3960-3962.
12. Domingo E, ed (2005) Virus entry into error catastrophe as a new antiviral strategy. Virus Res 107: 115-228.
13. Graci JD, Cameron CE (2002) Quasispecies, error catastrophe, and the antiviral activity of ribavirin. Virology 298: 175-180.
14. Anderson JP, Daifuku R, Loeb LA (2004) Viral error catastrophe by mutagenic nucleosides. Annu Rev Microbiol 58: 183-205.
15. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JYN, et al. (2000) The broad-spectrum antiviral ribonucleotide, ribavirin, is an RNA virus mutagen. Nature Medicine 6: 1375-1379.
16. Crotty S, Cameron CE, Andino R (2001) RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci USA 98: 6895-6900.
17. Crotty S, Cameron C, Andino R (2002) Ribavirin's antiviral mechanism of action: lethal mutagenesis? J Mol Med 80: 86-95.
18. Airaksinen A, Pariente N, Menendez-Arias L, Domingo E (2003) Curing of foot-and-mouth disease virus from persistently infected cells by ribavirin involves enhanced mutagenesis. Virology 311: 339-349.
19. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV, et al. (2002) Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. J Virol 76: 8505-8517.
20. Vo NV, Young KC, Lai MMC (2003) Mutagenic and inhibitory effects of ribavirin on hepatitis C virus RNA polymerase. Biochemistry 42: 10462-10471.
21. Freistadt MS, Meades GD, Cameron CE (2004) Lethal mutagens: broad-spectrum antivirals with limited potential for development of resistance? Drug Resist Updat 7: 19-24.
22. Maag D, Castro C, Hong Z, Cameron CE (2001) Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J Biol Chem 276: 46094-46098.
23. Lanford RE, Chavez D, Guerra B, Lau JY, Hong Z, et al. (2001) Ribavirin induces error-prone replication of GB virus B in primary tamarin hepatocytes. J Virol 75: 8074-8081.
24. Zhou S, Liu R, Baroudy BM, Malcolm BA, Reyes GR (2003) The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310: 333-342.
25. Kanda T, Yokosuka O, Imazeki F, Tanaka M, Shino Y, et al. (2004) Inhibition of subgenomic hepatitis C virus RNA in Huh-7 cells: ribavirin induces mutagenesis in HCV RNA. J Viral Hepat 11: 479-487.
26. Snell NJ (2001) Ribavirin-current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2: 1317-1324.
27. Parker WB (2005) Metabolism and antiviral activity of ribavirin. Virus Res 107: 165-171.
28. Asahina Y, Izumi N, Enomoto N, Uchihara M, Kurosaki M, et al. (2005) Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 43: 623-629.
29. Chevaliez S, Brillet R, Lazaro E, Hezode C, Pawlotsky JM (2007) Analysis of ribavirin mutagenicity in human hepatitis C virus infection. J Virol 81: 7732-7741.
30. Perelson AS, Layden TJ (2007) Ribavirin: is it a mutagen for hepatitis C virus? Gastroenterology 132: 2050-2052.
31. Lutchman G, Danehower S, Song BC, Liang TJ, Hoofnagle JH, et al. (2007) Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 132: 1757-1766.
32. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS (2004) Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 432: 922-924.
33. Hong Z (2003) The role of ribavirin-induced mutagenesis in HCV therapy: a concept or a fact? Hepatology 38: 807-810.
34. Scheidel LM, Durbin RK, Stollar V (1987) Sindbis virus mutants resistant to mycophenolic acid and ribavirin. Virology 158: 1-7.
35. Pfeiffer JK, Kirkegaard K (2003) A single mutation in poliovirus RNA-dependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci USA 100: 7289-7294.
36. Pfeiffer JK, Kirkegaard K (2005) Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J Virol 79: 2346-2355.
37. Sierra M, Airaksinen A, González-López C, Agudo R, Arias A, et al. (2007) Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol 81: 2012-2024.
38. Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, et al. (2003) Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38: 869-878.
39. Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE (2005) Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J Biol Chem 280: 25706-25716.
40. Castro C, Arnold JJ, Cameron CE (2005) Incorporation fidelity of the viral RNA-dependent RNA polymerase: a kinetic, thermodynamic and structural perspective. Virus Res 107: 141-149.
41. Pfeiffer JK, Kirkegaard K (2005) Increased fidelity reduces poliovirus fitness under selective pressure in mice. PLoS Pathogens 1: 102-110.
42. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R (2006) Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439: 344-348.
43. Vignuzzi M, Wendt E, Andino R (2008) Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 14: 154-161.
44. Ferrer-Orta C, Arias A, Escarmis C, Verdaguer N (2006) A comparison of viral RNA-dependent RNA polymerases. Curr Opin Struct Biol 16: 27-34.
45. Arias A, Arnold JJ, Sierra M, Smidansky ED, Domingo E, et al. (2008) Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-and-mouth disease virus mutant with reduced sensitivity to ribavirin. J Virol 82: 12346-12355.
46. Sierra S, Dávila M, Lowenstein PR, Domingo E (2000) Response of foot-and-mouth disease virus to increased mutagenesis. Influence of viral load and fitness in loss of infectivity. J Virol 74: 8316-8323.
47. González-López C, Gómez-Mariano G, Escarmís C, Domingo E (2005) Invariant aphthovirus consensus nucleotide sequence in the transition to error catastrophe. Infection Genetics and Evolution 5: 366-374.
48. Pariente N, Sierra S, Lowenstein PR, Domingo E (2001) Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J Virol 75: 9723-9730.
49. Pariente N, Airaksinen A, Domingo E (2003) Mutagenesis versus inhibition in the efficiency of extinction of foot-and-mouth disease virus. J Virol 77: 7131-7138.
50. Belsham GJ, Normann P (2008) Dynamics of picornavirus RNA replication within infected cells. J Gen Virol 89: 485-493.
51. Pincus SE, Wimmer E (1986) Production of guanidine-resistant and -dependent poliovirus mutants from cloned cDNA: mutations in polypeptide 2C are directly responsible for altered guanidine sensitivity. J Virol 60: 793-796.
52. García-Arriaza J, Ojosnegros S, Dávila M, Domingo E, Escarmis C (2006) Dynamics of mutation and recombination in a replicating population of complementing, defective viral genomes. J Mol Biol 360: 558-572.
53. Escarmis C, Lazaro E, Arias A, Domingo E (2008) Repeated bottleneck transfers can lead to non-cytocidal forms of a cytopathic virus: implications for viral extinction. J Mol Biol 376: 367-379.
54. Agudo R, Arias A, Pariente N, Perales C, Escarmis C, et al. (2008) Molecular characterization of a dual inhibitory and mutagenic activity of 5-fluorouridine triphosphate on viral RNA synthesis. Implications for lethal mutagenesis. J Mol Biol 382: 652-666.
55. Novella IS, Duarte EA, Elena SF, Moya A, Domingo E, et al. (1995) Exponential increases of RNA virus fitness during large population transmissions. Proc Natl Acad Sci USA 92: 5841-5844.
56. Escarmís C, Dávila M, Domingo E (1999) Multiple molecular pathways for fitness recovery of an RNA virus debilitated by operation of Muller's ratchet. J Mol Biol 285: 495-505.
57. Ho DD (1995) Time to hit HIV, early and hard. N Engl J Med 333: 450-451.
58. Domingo E (1989) RNA virus evolution and the control of viral disease. Prog Drug Res 33: 93-133.
59. Domingo E, Grande-Perez A, Martin V (2008) Future prospects for the treatment of rapidly evolving viral pathogens: insights from evolutionary biology. Expert Opin Biol Ther 8: 1455-1460.
60. Nijhuis M, van Maarseveen NM, Boucher CA (2009) Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases. Handb Exp Pharmacol. pp 299-320.
61. Bonhoeffer S, May RM, Shaw GM, Nowak MA (1997) Virus dynamics and drug therapy. Proc Natl Acad Sci USA 94: 6971-6976.
62. Le Moing V, Chene G, Carrieri MP, Alioum A, Brun-Vezinet F, et al. (2002) Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen. AIDS 16: 21-29.
63. Van Vaerenbergh K, Harrer T, Schmit JC, Carbonez A, Fontaine E, et al. (2002) Initiation of HAART in drug-naive HIV type 1 patients prevents viral breakthrough for a median period of 35.5 months in 60% of the patients. AIDS Res Hum Retroviruses 18: 419-426.
64. Nájera I, Richman DD, Olivares I, Rojas JM, Peinado MA, et al. (1994) Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Res Hum Retroviruses 10: 1479-1488.
65. Nájera I, Holguín A, Quiñones-Mateu ME, Muñoz-Fernández MA, Nájera R, et al. (1995) Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 69: 23-31.
66. Johnson JA, Li JF, Wei X, Lipscomb J, Irlbeck D, et al. (2008) Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 5: e158.
67. Cubero M, Esteban JI, Otero T, Sauleda S, Bes M, et al. (2008) Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 370: 237-245.
68. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, et al. (2008) Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48: 1769-1778.
69. Domingo E, Escarmis C, Lazaro E, Manrubia SC (2005) Quasispecies dynamics and RNA virus extinction. Virus Res 107: 129-139.
70. Bull JJ, Sannjuán Ra, Wilke CO (2008) Lethal mutagenesis. In: Origin and Evolution of Viruses, Domingo E, Parrish C, Holland JJ, eds. Elsevier. pp 207-218.
71. González-López C, Arias A, Pariente N, Gómez-Mariano G, Domingo E (2004) Preextinction viral RNA can interfere with infectivity. J Virol 78: 3319-3324.
72. Grande-Pérez A, Lazaro E, Lowenstein P, Domingo E, Manrubia SC (2005) Suppression of viral infectivity through lethal defection. Proc Natl Acad Sci USA 102: 4448-4452.
73. Perales C, Mateo R, Mateu MG, Domingo E (2007) Insights into RNA virus mutant spectrum and lethal mutagenesis events: replicative interference and complementation by multiple point mutants. J Mol Biol 369: 985-1000.
74. Escarmís C, Dávila M, Charpentier N, Bracho A, Moya A, et al. (1996) Genetic lesions associated with Muller's ratchet in an RNA virus. J Mol Biol 264: 255-267.
75. Escarmís C, Gómez-Mariano G, Dávila M, Lázaro E, Domingo E (2002) Resistance to extinction of low fitness virus subjected to plaque-to-plaque transfers: diversification by mutation clustering. J Mol Biol 315: 647-661.
76. Pariente N, Sierra S, Airaksinen A (2005) Action of mutagenic agents and antiviral inhibitors on foot-and-mouth disease virus. Virus Res 107: 183-193.
77. Ferrer-Orta C, Arias A, Perez-Luque R, Escarmis C, Domingo E, et al. (2004) Structure of foot-and-mouth disease virus RNA-dependent RNA polymerase and its complex with a template-primer RNA. J Biol Chem 279: 47212-47221.
78. Ferrer-Orta C, Arias A, Perez-Luque R, Escarmis C, Domingo E, et al. (2007) Sequential structures provide insights into the fidelity of RNA replication. Proc Natl Acad Sci U S A 104: 9463-9468.
79. Smidansky ED, Arnold JJ, Cameron CE (2008) Nucleic acid polymerase fidelity and viral population fitness. In: Origin and Evolution of Viruses, Domingo E, Parrish C, Holland JJ, eds. Elsevier. pp 135-160.
80. de la Torre JC, Alarcón B, Martínez-Salas E, Carrasco L, Domingo E (1987) Ribavirin cures cells of a persistent infection with foot-and-mouth disease virus in vitro. J Virol 61: 233-235.
81. Sobrino F, Dávila M, Ortín J, Domingo E (1983) Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology 128: 310-318.
82. Ghoshal K, Jacob ST (1997) An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem Pharmacol 53: 1569-1575.
83. Parker WB, Cheng YC (1990) Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48: 381-395.
84. Page T, Connor JD (1990) The metabolism of ribavirin in erythrocytes and nucleated cells. Int J Biochem 22: 379-383.
85. Graci JD, Cameron CE (2006) Mechanisms of action of ribavirin against distinct viruses. Rev Med Virol 16: 37-48.
86. Zhang Y, Jamaluddin M, Wang S, Tian B, Garofalo RP, et al. (2003) Ribavirin treatment up-regulates antiviral gene expression via the interferon-stimulated response element in respiratory syncytial virus-infected epithelial cells. J Virol 77: 5933-5947.
87. Consensus Panel (2002) National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002-June 10-12, 2002. Hepatology 36: S3-S20.
88. Connor E, Morrison S, Lane J, Oleske J, Sonke RL, et al. (1993) Safety, tolerance, and pharmacokinetics of systemic ribavirin in children with human immunodeficiency virus infection. Antimicrob Agents Chemother 37: 532-539.
89. Gilbert BE, Knight V (1986) Biochemistry and clinical applications of ribavirin. Antimicrob Agents Chemother 30: 201-205.
90. Ogle JW, Toltzis P, Parker WD, Alvarez N, McIntosh K, et al. (1989) Oral ribavirin therapy for subacute sclerosing panencephalitis. J Infect Dis 159: 748-750.
91. Sanz-Ramos M, Diaz-San Segundo F, Escarmis C, Domingo E, Sevilla N (2008) Hidden virulence determinants in a viral quasispecies in vivo. J Virol 82: 10465-10476.
92. Domingo E, Davila M, Ortin J (1980) Nucleotide sequence heterogeneity of the RNA from a natural population of foot-and-mouth-disease virus. Gene 11: 333-346.
93. García-Arriaza J, Manrubia SC, Toja M, Domingo E, Escarmís C (2004) Evolutionary transition toward defective RNAs that are infectious by complementation. J Virol 78: 11678-11685.